Appeal No. 2007-0054
Application No. 08/846,722
1. A method for treating a disease state in mammals caused by
mammalian nasal and sinus cells involved in the inflammatory response
comprising contacting the mammalian nasal and sinus cells with an
inflammatory mediator; wherein the inflammatory mediator is present in an
amount capable of reducing the undesired inflammatory response, is an
antioxidant, and is selected from the group consisting of pyruvate and a
pyruvate precursors, wherein the pyruvate precursor is not propylene glycol.
18. The method of claim [1, further comprising contacting the
mammalian nasal and sinus cells with a therapeutic agent], wherein the
therapeutic agent is oxymetazoline.
27. A method for the treatment of rhinitis, eosinophilia syndrome,
and sinusitis, comprising administering a nasal solution to the nostrils of a
patient in need thereof, wherein the nasal moisturizing saline solution
comprises:
a) water,
b) sodium chloride, 0.65% by weight,
c) pyruvate, at least 0.1mM,
d) buffer, and optionally,
e) a preservative;
wherein the nasal moisturizing saline solution is buffered and made isotonic.
Thus, claim 1 is directed to a “method for treating a disease state in
mammals caused by mammalian nasal and sinus cells involved in the
inflammatory response.” The method comprises contacting the nasal and
sinus cells with pyruvate or a pyruvate precursor other than propylene
3
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: September 9, 2013